Status and phase
Conditions
Treatments
About
This is a randomized, single-blind, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
112 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Jiang hua Chen, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal